Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Endo Pharma Files Amendment To Its Citizen Petition With FDA - Quick Facts

RELATED NEWS
Trade ENDP now with 

Endo Pharmaceuticals (ENDP: Quote) said it has filed an amendment to its Citizen Petition with the FDA calling on FDA to publicly address numerous concerns raised by Endo and other experts about approval requirements for generic versions of LIDODERM, or lidocaine patch 5%.

The amended Citizen Petition highlights the growing scientific and regulatory support for requiring generic manufacturers to conduct comparative clinical endpoint studies to demonstrate bioequivalence to locally acting topical products like LIDODERM. The amended Citizen Petition also raises several new issues that need to be resolved before FDA approves a generic formulation of LIDODERM.

The amended Citizen Petition asks FDA to address the repeated public statements by scientific experts and FDA officials that pharmacokinetic studies, which measure the level of a drug in the bloodstream, have not yet been validated as a bioequivalence method for locally acting topical drugs like LIDODERM.

The amendment also points out that FDA has not produced any evidence indicating that pharmacokinetic studies are sufficiently sensitive to determine whether a proposed generic product will replicate LIDODERM's clinical effect.

Ivan Gergel, Executive Vice President of R&D and Chief Scientific Officer at Endo, said, "..FDA must publicly address the many unanswered questions from the original petition, as well as the additional concerns raised in this amendment, before taking any formal steps toward the approval of a generic version of LIDODERM."

Register
To receive FREE breaking news email alerts for Endo International plc and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
LinkedIn Corp., the world's largest online professional network, said Thursday after the markets closed that it swung to a second quarter loss, hurt by higher costs and expenses even as revenue surged 47%. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations as did its quarterly revenue. Kraton Performance Polymers, Inc. (KRA), Wednesday reported second-quarter net income of $11.1 million or $0.33 per share, up from $3.8 million or $0.12 per share last year. Adjusted earnings improved to $0.46 per share from $0.15 per share last year. Revenues for the quarter dropped to $323.8... Organic grocer Whole Foods Market, Inc. said Wednesday after the markets closed that its third quarter profit rose 6.3% from last year, as same-store sales increased 3.9%. The company's quarterly earnings per share also came in above analysts' expectations, but its quarterly sales fell shy of analyst' forecast.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.